Inozyme Pharma Inc. (INZY)
1.50
-0.22 (-12.79%)
At close: Jan 14, 2025, 3:59 PM
1.49
-0.33%
Pre-market Jan 15, 2025, 04:00 AM EST
undefined% (undefined)
| Bid | 1.18 |
| Market Cap | 96.04M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.55 |
| PE Ratio (ttm) | -0.96 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.49 |
| Volume | 1,424,438 |
| Avg. Volume (20D) | 589,057 |
| Open | 1.71 |
| Previous Close | 1.72 |
| Day's Range | 1.45 - 1.77 |
| 52-Week Range | 1.45 - 7.79 |
| Beta | undefined |
About INZY
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for spec...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 59
Stock Exchange NASDAQ
Ticker Symbol INZY
Website https://www.inozyme.com
Analyst Forecast
According to 8 analyst ratings, the average rating for INZY stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 970.23% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 days ago ·
Source
-14%
Inozyme Pharma shares are trading lower after mult...
Unlock content with
Pro Subscription
9 months ago ·
Source
+8.83%
Inozyme Pharma shares are trading higher after the company announced that it will discuss topline data from its ongoing Phase 1/2 trial of INZ-701 in adults with ABCC6 Deficiency, and from all cohorts of its ongoing Phase 1/2 trial of INZ-701 in adults with ENPP1 Deficiency.
